32 results about "Enteropathy" patented technology

The invention discloses a non-invasive intestinal flora fixed-point sampling and drug release device, and belongs to the technical field of micro-ecological diagnosis and treatment. The device comprises a shell, an internal storage bin, a medicine loading cavity and a channel switching mechanism. The shell adopts a capsule-shaped design, and an enteric coating is arranged on the surface of the shell, so that the function is started after the shell reaches a specified position of an intestinal tract. Through the internal ingenious mechanism linkage design, the device can firstly complete non-invasive fixed-point sampling of intestinal contents, and after the sampling action is completed, a drug release mechanism is automatically triggered, so that accurate drug delivery of the same part is realized. Cooperative operation of sampling and drug release in time sequence and space is achieved, and the problems of pain, disjunction of the diagnosis and treatment process, poor drug targeting and the like caused by traditional invasive operation are effectively solved. The device is flexible in structural design, has the advantages of being noninvasive, efficient, accurate in time sequence control and the like, and is suitable for integrated application of diagnosis and treatment of various digestive tract diseases such as inflammatory bowel disease management, micro-ecological regulation and the like.

The present invention relates to anti-CD 103 antibodies, as well as use of these antibodies in diagnosis, prognosis, monitoring, and treatment of diseases. Also disclosed is an imaging agent comprising the anti-CD 103 antibody and a detectable label, wherein the antibody either does not block CD 103 binding to E-cadherin or at least partially blocks CD 103 binding to E-cadherin. The methods of treatment involve administering the anti CD 103 antibody which may be optionally coupled to a cytotoxic agent. Diseases to be treated include e.g. Hairy Cell leukemia, HCLv, intestinal and extraintestinal lymphomas, enteropathy-associated T-cell lymphoma (EATL), T-lymphoblastic leukemia / lymphoma (T-ALL), T-cell prolymphocytic leukemia (T-PLL), adult T cell leukemia / lymphoma (ATLL), mycosis fungoides (ME), anaplastic large cell lymphoma ALCL, cutaneous T-cell lymphoma (CTCL), Sezary Syndrome (SS), Alzheimer's disease, Parkinson's disease or multiple sclerosis.

The present invention relates to pharmaceutical compounds of Formula (I):as further described herein, and pharmaceutical compositions containing such compounds, as well as methods of using these compounds to modulate the activity of aryl hydrocarbon receptor (AhR) and to treat conditions comprising inflammation inside the intestinal tract and certain disorders of the central nervous system affected by the gut-brain axis, including IBD, ulcerative colitis, Crohn's disease, Huntington's disease, and multiple sclerosis.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for treating ischemic bowel disease as well as a preparation method and application thereof. The traditional Chinese medicine composition is prepared from the following traditional Chinese medicine raw materials in parts by weight: 50-200 parts of radix salviae miltiorrhizae, 50-200 parts of caulis sargentodoxae, 50-200 parts of cortex moutan, 50-200 parts of radix paeoniae rubra and 100-250 parts of radix astragali. The traditional Chinese medicine composition disclosed by the invention has the effects of promoting blood circulation to remove blood stasis, promoting qi circulation to relieve pain, tonifying spleen and clearing damp, and can be used for clinically treating ischemic bowel disease and liver and lung injury caused by intestinal ischemia.

The invention discloses a lipidosome composite hydrogel microsphere for repairing damaged intestinal mucosa and a preparation method thereof, LHMs (at) 4-OI is composed of hyaluronic acid modified targeted drug-loaded lipidosome, sodium alginate, hydrochloric acid treated sucralfate and a CaCl cross-linking agent, and rapid gel forming is carried out under the voltage of 11.0 KV through an electrospray technology. The microspheres have pH responsiveness and gastric juice digestion resistance, CD44 receptor targeting is achieved through hyaluronic acid modification, sodium alginate and Ca form an egg box structure to provide a three-dimensional network, and sucralfate enhances adhesion to isolate harmful substances. The preparation method comprises the steps of preparation of the drug-loaded liposome by a film hydration method, hyaluronic acid modification and electrospray crosslinking, is simple to operate and low in cost, and can be used for large-scale production. The microspheres can effectively load an anti-inflammatory drug 4-OI, inhibit expression of inflammatory factors and promote self-repair of damaged intestinal mucosa, and have wide application prospects in the fields of abdominal infection, inflammatory bowel diseases, colorectal cancer and the like.

The application discloses a kind of compositions for treating radiation enteropathy and application thereof, belong to medical technology field.The composition includes the following components: anemarrhena asphodeloides B4, obakunine, berberine, aesculetin, fraxinellone and fraxinellin.The composition has no toxic side effects, has good safety, can reduce the inflammatory infiltration of intestinal epithelial cells, reduce intestinal epithelial cell apoptosis, protect intestinal barrier and protect intestinal oxidative damage by regulating NF-κB, Caspase 9 / 3 and NRF2 pathway, and then multi-component, multi-pathway jointly play the efficacy of treating radiation enteropathy.The problem that there is no effective drug for treating radiation enteropathy in the prior art is solved.

The invention provides a medicine for preventing or treating enteritis. Hamp is adopted; and E, dyeing, determination of IL-6 factors in serum of each group of animals and the like are used for researching the influence of the vocyclosporine on intestinal tissues, mucosal barriers and immune systems of DSS or TNBS-induced mouse colitis models. Experimental basis is provided for clinical application of the vocyclosporine in preparation of the colitis treatment medicine, and the vocyclosporine has good application prospects and huge potential value and social significance.

The application discloses a composition for treating radiation enteropathy and application thereof, and belongs to the technical field of biological medicine, and solves the problem that there is no effective treatment drug for radiation enteropathy at present. The composition comprises puerarin, baicalein, berberine and glycyrrhetinic acid. The composition for treating radiation enteropathy can regulate Wnt / beta-catenin, NF-kappa B and Caspase-9 / 3 signal pathways and the like, promote the proliferation of intestinal cells after radiation damage, reduce the inflammation level of intestinal tissues after radiation, reduce the apoptosis of intestinal cells after radiation and the like, improve the radiation damage of intestinal epithelial cells, play an anti-radiation enteropathy role, and has a remarkable effect on treating radiation enteropathy.

A method for identifying the risk of chronic enteropathy, includes receiving new patient data, receiving a machine-learning based diagnostic model and a knowledge based diagnostic model, determining whether the machine-learning based diagnostic model indicates a risk for chronic enteropathy for the new patient data, and in a case where the machine-learning based diagnostic model indicates a risk for chronic enteropathy for the new patient data, assessing the risk of chronic enteropathy using the knowledge based diagnostic model.

The application discloses a GLP-2 analogue and application thereof, and belongs to the technical field of biological medicines. The GLP-2 analogue is an oligopeptide formed by 1-5 amino acids at the N end of tildipirosin, the oligopeptide retains GLP-2 analogue activity, effectively improves the disease degree of intestinal injury enteropathy, and the effect is equivalent to that of tildipirosin; and since the oligopeptide only includes 5 amino acids, the difficulty and cost of preparation are significantly reduced, so that the development cost of clinical drugs is reduced, and the medication cost of the GLP-2 analogue is expected to be reduced.

A method for treating and / or improving inflammatory intestinal disease includes administering a composition to a patient suffering from inflammatory intestinal disease to be capable of effectively inhibiting the patient's intestinal bleeding, intestinal inflammation, and capable of achieving efficacies of repairing intestinal cells and intestinal wall structure. The composition contains an effective amount of bromelain and / or an effective amount of Bidens pilosa extract.

The utility model belongs to the technical field of stoma drainage tubes, and particularly relates to a lavage drainage device for intestinal diseases, which comprises a communication box, a first lavage tube is fixedly mounted at the top of one side of the communication box, a drainage tube is fixedly mounted in the communication box, a second lavage tube is fixedly mounted at the bottom of the other side of the communication box, and a drainage tube is fixedly mounted in the second lavage tube. The drainage tube is sleeved with the second lavage tube, a liquid storage cavity is formed in the communicating box, a circular clamping frame is fixedly installed at the tail end of the second lavage tube, and a plurality of liquid leakage holes are formed in the bottom of the circular clamping frame. Through the structural design of the communicating box, the first lavage tube, the drainage tube, the second lavage tube, the liquid storage cavity, the circular clamping frame and the liquid leakage hole, the function of reducing discomfort of a patient is achieved, lavage and drainage can be completed at the same time through one insertion point, the puncture frequency and wounds caused by puncture are reduced, meanwhile, an open area exposed in the external environment is reduced, and the operation is convenient. Therefore, the infection risk is reduced.

The invention relates to lactobacillus amylovorans and an application thereof in intestinal diseases, the lactobacillus amylovorans (LA) is named as lactobacillus amylovorans QC1H, is preserved in China Center for Type Culture Collection on March 28, 2023, and has a preservation number of CCTCC NO: M2023427, the lactobacillus amylovorans and / or a fermentation product thereof can significantly improve the ratio of mouse intestinal villus length to crypt depth, and the lactobacillus amylovorans and / or the fermentation product thereof can significantly improve the intestinal villus length and crypt depth of mice. The compound has the advantages of reducing mouse ileum enteritis factor expression, improving ileum tight junction protein expression and reducing intestinal permeability, and has important application significance and value in preparation of a therapeutic agent for preventing and treating enteritis caused by aflatoxin B1 (AFB1).

The application discloses a traditional Chinese medicine pair for treating radiation enteropathy and application thereof, and relates to the technical field of traditional Chinese medicine preparation. The traditional Chinese medicine pair comprises the following components in parts by weight: 2-20 parts of cortex fraxini and 2-20 parts of radix scrophulariae. The cortex fraxini has the effects of astringing and stopping dysentery, the radix scrophulariae has the effects of clearing heat and drying dampness, and the cortex fraxini and the radix scrophulariae have the effects of clearing heat and resolving toxins, invigorating the spleen and removing dampness, and astringing intestines and stopping dysentery, and have the effect of treating radiation enteropathy. The application solves the problem that effective drugs for treating radiation enteropathy are lacked in the prior art.

The present invention discloses an application of tea lovage polysaccharide in the preparation of a drug for regulating intestinal flora in inflammatory bowel disease, and belongs to the technical field of polysaccharide extraction process optimization and intestinal flora regulation. Specifically, the present invention provides an economical and efficient extraction process and new use of tea lovage polysaccharide for the preparation of a preparation or composition. By increasing the relative abundance of probiotic flora, reducing the relative abundance of harmful bacteria, regulating the structure of intestinal flora, etc., the symptoms of intestinal flora disorder in inflammatory bowel disease are alleviated and treated. Tea lovage polysaccharide improves ulcerative colitis in mice by upregulating the relative abundance of probiotics such as Bacteroides and Faecalibacterium prausnitzii, and downregulating the relative abundance of pathogenic bacteria such as Proteobacteria, Gammaproteobacteria, Enterobacteriaceae and Escherichia, thereby reversing the abnormal proliferation of bacteria in mice with inflammatory bowel disease and improving the disordered intestinal flora in mice with inflammatory bowel disease.

The application discloses sulfhydrylated oxidized guar gum / sodium alginate microspheres and a preparation method and application thereof, and belongs to the field of biomedical materials. The sulfhydrylated oxidized guar gum and a sodium alginate base material are used to prepare and construct microspheres with pH response, colon targeting and intestinal adhesion by an emulsion gel method, the microsphere technology is used to embed probiotics, and the survival rate of the probiotics in gastric juice is improved. Through in-vitro verification, the method of embedding the microspheres successfully prevents the direct contact of the probiotics with a harsh environment, improves the ability of the probiotics to resist strong acid in the gastrointestinal tract, and enhances the adhesion and colonization effect of the probiotics in the intestinal tract. Through an animal experiment of simulating colitis, the LGG microspheres have the best treatment effect on colitis. Compared with a large number of side effects caused by antibiotic therapy, the treatment method has a certain clinical application prospect as a means with biological safety to treat inflammatory bowel disease.

The present invention relates to a compound of Formula (I), in particular, the compound of Formula (II) or an isotopic variant, a pharmaceutically acceptable salt or solvate thereof for use in a method of treatment of bile acid diarrhea (BAD) or autoimmune enteropathy (AIE) in a subject in need thereof.

The application discloses a kind of polydopamine-coated inulin-chitosan composite microspheres loaded with garlic exosomes and a preparation method and application thereof, the composite microspheres are formed by Schiff base reaction of aldehyde inactivated inulin and chitosan to form hydrogel framework, embedding garlic-derived exosome-like nanoparticles inside, and coating polydopamine layer on the surface.The application is prepared by microfluidic electrospray technology, and the obtained microspheres have uniform particle size, controllable structure and good biocompatibility.The composite microspheres are stable in gastric juice, degrade responsively in colon environment and release exosomes, and the polydopamine layer enhances intestinal mucosa adhesion and retention.The microspheres have anti-inflammatory, antioxidant, macrophage polarization regulation, intestinal barrier repair and intestinal flora regulation functions, and can be used for preparing drugs or oral preparations for preventing or treating inflammatory bowel disease (especially colitis).

The present invention relates to a feed composition for preventing or improving chronic enteropathy and adverse dietary reactions, wherein, according to one aspect, the feed composition for preventing or improving chronic enteropathy and adverse dietary reactions may include omega-3 fatty acids and butyric acid.

The disclosure provides methods and materials for detecting endogenous IgA antibodies to one or more, or all, of OmpC (ACA), Ki67 (AKiA), TK1, integrin (AINTA) and keratin (AKERA), which are useful to

The invention relates to application of Metrnl in prevention and treatment of radioactive bowel diseases. The Metrnl is used for preventing and treating the radiation bowel disease for the first time, and the expression of the intestinal epithelial cell Metrnl is related to the radiation bowel disease. By establishing a Metrnl intestinal epithelial cell specific knockout and overexpression mouse model, it is proved that damage after irradiation is aggravated due to the fact that intestinal epithelial cells lack Metrnl, and a Metrnl intestinal specific overexpression mouse can relieve radiation damage. In a cell model, DNA damage caused by ionizing radiation after Metrnl knockdown is aggravated, the cell proliferation capacity is weakened, Metrnl overexpression can resist ionizing radiation damage, and METRNL recombinant protein has prevention and treatment effects on ionizing radiation damage. The invention proves that Metrnl has the effect of preventing and treating radioactive bowel diseases for the first time, and the protection mechanism of Metrnl is related to the reduction of DNA damage of intestinal cells.

The present invention pertains to animal plasma for use in the treatment and / or prevention of enteropathy, preferably chronic enteropathy, caused by a pathogen, wherein the animal plasma is obtained from an animal selected from the group consisting of porcine, bovine and ovine. The invention further pertains to compositions comprising the animal plasma for use according to the invention. Preferably the treatment and / or prevention of enteropathy is in an animal, such as a dog or cat.

To provide pharmaceutical formulations for treating or preventing C5-related diseases. [Solution] A pharmaceutical formulation for use in a method of treating CD55 deficiency accompanied by complement hyperactivation, vascular thrombosis, and protein-losing enteropathy (CHAPLE disease) in a subject, wherein the pharmaceutical formulation comprises an antibody or antigen-binding fragment thereof that specifically binds to C5 and includes three heavy chain complementarity-determining regions of a heavy chain variable region (HCVR) containing a specific amino acid sequence, and three light chain complementarity-determining regions of a light chain variable region (LCVR) containing a specific amino acid sequence, wherein the subject has hypoalbuminemia and is determined to have a CD55 loss-of-function mutation by genetic analysis.

The present invention provides lactic acid bacteria (LAB) which have been engineered to express a therapeutic protein capable of promoting resolution of inflammation and / or wound healing for use in treating or preventing therapy-induced enteropathy in a human or animal subject.

The application relates to the field of intelligent medical treatment, in particular to a method, equipment and program product for identifying rare intestinal diseases. The method comprises the following steps: acquiring pathological data of a to-be-detected person; the pathological data comprises goblet cells, Paneth cells, neutrophilic granulocytes and plasma cells; the type of the rare intestinal disease of the to-be-detected person is determined based on the pathological data, the type of the rare intestinal disease comprises autoimmune enteropathy and common variant immunodeficiency; when any two or more of the following conditions are met, namely, the number of goblet cells is less than a preset threshold, the number of Paneth cells is less than a preset threshold, neutrophilic granulocyte infiltration occurs, and the number of plasma cells remains unchanged, the to-be-detected person is determined to have autoimmune enteropathy; and when the number of plasma cells is less than a preset threshold, the to-be-detected person is determined to have common variant immunodeficiency. The application can effectively distinguish the types of rare intestinal diseases and has good clinical value.

The application relates to a kind of organic intestinal disease type evaluation method and device based on confidence rule base reasoning.The input and output characteristics of BRB-ER model are determined according to the clinical data of organic intestinal disease;The collected clinical data of patients is coded and converted and given semantic value, an initial rule base is established, and the rule weight of confidence rule base and the confidence parameter of output result are set;The input feature vector is converted into corresponding matching degree calculation;Calculate the activation weight corresponding to the activated rule;The activated rule is inferred and fused through ER algorithm to obtain the confidence distribution result;According to the type evaluation result, the confidence rule base of colorectal cancer and ischemic intestinal disease is analyzed and optimized, and the optimal evaluation result is obtained.The application can establish the nonlinear complex relationship between the input characteristics and the evaluation result of organic intestinal disease, and provide active assistance to the doctor, effectively improve the accuracy of organic intestinal disease type evaluation.

New and useful computer-implemented methods; methods of identifying markers associated with enteropathies; methods of determining the level of severity of an enteropathy; and determining a treatment for an enteropathy; are disclosed. In addition, the present disclosure provides methods of identifying a biological response to one or more treatments for an enteropathy, and whether a given treatment to an enteropathy results in a therapeutic or adverse effect, as determined in a spatiotemporal manner throughout the entirety of the small bowel, or a region of interest therein.

The disclosures herein relate to novel compounds of the formula (1) such as e.g. 1H-pyridazino[4,3-e][1,3,4]thiadiazine and spiro[cyclopropane-1,5'-pyridazino[4,3-e][1,3]thiazine] derivatives, as GPR65 agonists for the treatment of inflammatory diseases including inflammatory bowel disease (IBD), atopic dermatitis (AD) and asthma; treatment of bone resorption diseases, including osteoporosis; neuroinflammatory disorders, including multiple sclerosis (MS).

This invention relates to anti-CD103 antibodies and their use in the diagnosis, prognosis, monitoring, and treatment of diseases. An imaging agent comprising the anti-CD103 antibody and a detectable label is also disclosed, wherein the antibody does not block CD103 binding to E-cadherin or at least partially blocks CD103 binding to E-cadherin. Treatment methods involve administering the anti-CD103 antibody, optionally conjugated to a cytotoxic agent. Diseases that need to be treated include, for example, hairy cell leukemia, HCLv, intestinal and extraintestinal lymphoma, enteropathy-associated T-cell lymphoma (EATL), T-lymphoblastic leukemia / lymphoma (T-ALL), T-cell prolymphocytic leukemia (T-PLL), adult T-cell leukemia / lymphoma (ATLL), mycosis fungoides (ME), anaplastic large cell lymphoma ALCL, cutaneous T-cell lymphoma (CTCL), Cezari syndrome (SS), Alzheimer's disease, Parkinson's disease, or multiple sclerosis.

The present invention provides a method of treating a disease mediated by NLRP3 inflammasomes in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of compound 2′,4′-dihydroxychalcone. The compound 2′,4′-dihydroxychalcone inhibits the activation of NLRP3 inflammasomes and reduces the secretion level of pro-inflammatory factors by inhibiting the activation of Caspase-1 and the expression of NLRP3.